Oddo Seydler Bank AG issued a report on MorphoSys (ETR:MOR), boosting its stock price target to 66.00EUR today
- Updated: October 5, 2016
MorphoSys (ETR:MOR) had its target price raised to 66.00EUR by Oddo Seydler Bank AG in a report released 10/5/2016. The new target price indicates a possible upside of 0.49% based on the company's last closing price.
Previously on 10/04/2016, HSBC reported on MorphoSys (ETR:MOR) raised the target price from 0.00EUR to 43.00EUR. At the time, this indicated a possible downside of -0.02%.
Yesterday MorphoSys (ETR:MOR) traded 0.00% even at 44.35EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of MOR traded, down from an avg. volume of 42,448
See Chart Below
MorphoSys has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR The company’s market cap is currently 0 EUR.
General Information About MorphoSys (ETR:MOR)
MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.